Medicare's coverage-with-evidence-development decision still shapes the rollout
The CMS coverage framework requiring registry participation has had measurable effects on which sites prescribe and where patients get treated.
Reimbursement design did more to shape the anti-amyloid rollout than any clinical guideline.
CMS's coverage-with-evidence-development (CED) framework requires that anti-amyloid antibody prescribing be tied to participation in a qualifying registry, with structured data submission on patient characteristics, treatment course, and outcomes.
The intent was straightforward: collect real-world evidence to inform durable coverage decisions. The operational consequence has been less neutral. Sites without registry infrastructure — typically smaller community practices — have been slower to prescribe. Sites with research operations already in place have absorbed it more easily. The result is a rollout shape that mirrors clinical-trial geography more than community-care geography.
Two questions remain open:
- Will the data collected actually inform coverage refinements — for instance, whether ARIA risk warrants APOE4-specific coverage rules.
- Whether the registry burden eases over time, or hardens into a permanent feature of high-cost neurology care.
The CED model is being watched as a template for other emerging neurodegenerative therapies. Its perceived success or failure here will influence what the next wave of approvals looks like.
Key sources
- CMS National Coverage Determination 200.3 — monoclonal antibodies directed against amyloid for Alzheimer's
- CMS Alzheimer's anti-amyloid registry program documentation
- Published health-system reports on registry-tied prescribing patterns